Breaking Age Barriers: The Benefits of CAR T-Cell Therapies in Treating Large B-Cell Lymphoma in Older Patients

Abstract

The management of relapsed/refractory diffuse large B-cell lymphoma (DLBCL) in older patients is challenging due to increased morbidity, toxicity and reduced effectiveness of therapy in this vulnerable and difficult-to-treat population. Chimeric antigen receptor (CAR) T-cell therapies have become a breakthrough in the treatment of lymphoid malignancies, including DLBCL. Although CAR T-cell immunotherapy may significantly improve clinical outcomes, its toxicity raised concerns as to whether this therapeutic approach is beneficial for geriatric patients. The current paper summarizes the data from recent studies that evaluated the efficacy and safety of CAR T-cell products in older patients with DLBCL. PEER REVIEWED ARTICLE Peer reviewers: Dr Wiebke Rösler (University Hospital Zurich, Zurich, Switzerland); three anonymous peer reviewer. Submitted: November 16, 2023 CEST; Accepted: December 19, 2023 CEST